CSIMarket Company Name, Ticker, Industry, else..
 
Protokinetix Incorporated  (PKTX)
Other Ticker:  
 
 
Price: $0.0098 $0.00 -2.000%
Day's High: $0.0098 Week Perf: 0.00
Day's Low: $ 0.01 30 Day Perf: -2 %
Volume (M): 2 52 Wk High: $ 0.02
Volume (M$): $ 0 52 Wk Avg: $0.01
Open: $0.01 52 Wk Low: $0.01



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 382
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Protokinetix Incorporated
Protokinetix Incorporated is a biotechnology company based in Canada. The company specializes in developing and commercializing innovative therapeutics for the treatment of diseases. Protokinetix's key focus is on a proprietary technology known as AAGP' (Anti-Aging Glycoprotein), which has potential applications in various medical fields.

AAGP' is a peptide-based molecule that has shown promising results in preclinical studies, demonstrating its effectiveness in protecting cells from damage and improving their function. Protokinetix is currently conducting further research and development to explore the potential therapeutic applications of AAGP' in areas such as organ transplantation, cell and gene therapies, and regenerative medicine.

One of the notable advancements in Protokinetix's research is in the field of organ transplantation. The company has successfully demonstrated the ability of AAGP' to extend the viability and function of organs, potentially reducing the need for organ donors and improving outcomes for patients awaiting transplants.

Protokinetix Incorporated is committed to advancing its technology and bringing novel therapeutics to market. The company collaborates with academic institutions, research organizations, and industry partners to accelerate the development and commercialization of its products. Overall, Protokinetix's innovative approach and focus on AAGP' hold promise in the field of therapeutic interventions and improving patient outcomes.


   Company Address: 109 W Main St Dalton 44618 OH
   Company Phone Number: 455-4971   Stock Exchange / Ticker: PKTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        9.33% 
BMY   -2.13%    
JNJ   -1.49%    
MRK        6.28% 
PFE        3.99% 
SNY        3.55% 
• View Complete Report
   



Protokinetix Incorporated

Protokinetix Inc.'s Operating Income Soars to $0.092026 Million in First Quarter of 2024



Protokinetix Incorporated, a major player in the pharmaceutical preparations sector, recently released its financial report for the first quarter of 2024. The company's operating income, derived from PKTX, stood at $0.092026 million for the period between January and March 2024. Although top-line figures were not disclosed, the information can still be analyzed by comparing it to the first quarter of 2023. Additionally, a deeper look at Protokinetix Incorporated's market and stock performance provides further context to the company's recent performance.
Financial Analysis:
During the first quarter of 2024, Protokinetix Incorporated ran the PKTX more efficiently, resulting in a reduction of diminishing returns to $-0.092 million. This indicates a significant improvement compared to the previous year, where the company reported an operating income of $0.107038 million. However, the operating earnings fell -14.02% to $0.092026 million, which affected the company's operating margin, squeezing it to 0% from 0% in Q1 2023. Although the absence of top-line figures makes it difficult to gauge the complete financial health of the company, the efforts to optimize PKTX operations show promising signs.
Protokinetix Incorporated

Protokinetix Incorporated Surges to Positive Operating Profit in Q4 2023

The financial results of Protokinetix Incorporated for the fourth quarter of 2023 raise some interesting points of discussion. While there were no significant changes in the top-line revenue during this reporting cycle, the company did manage to reduce its operating losses by a significant amount.
The operating profit for the Major Pharmaceutical Preparations company came in at $0.112473 million, a substantial improvement compared to the previous quarter. This indicates that the management team at Protokinetix Incorporated has been able to run the company more efficiently and effectively, resulting in a reduction of losses.
However, it is worth noting that the operating margin for the company has decreased to 0%, from 0% in the fourth quarter of 2022. This suggests that while the company has managed to cut its losses, there is still room for improvement in terms of profitability.
Looking at the overall financial performance of Protokinetix Incorporated for the full year 2023, the company reported a loss of $-0.42 million and revenue of $0.00 million. While the company did report a break-even compared to the previous year, there is still some uncertainty about how these results will impact the company going forward.
Protokinetix Incorporated

Protokinetix Incorporated Breaking Barriers in Pharma: Impressive Q3 Earnings Reflects Strong Growth



Protokinetix Incorporated, a major player in the pharmaceutical industry, recently released its earnings report for the third quarter of 2023. The results were not what shareholders expected as the company experienced a decline in operating income and increased losses compared to the previous year. However, there are indications of potential improvements in key areas, leading market participants to wonder if the company will bounce back in the near future. This article will delve into the details of Protokinetix's Q3 earnings report and analyze the implications for the company's future.
Operating Income Decline and Revenue Moderations
During the July to September period in 2023, Protokinetix's operating income decreased to $0.080391 million from $0.370042 million in the same quarter of 2022. This decline of 78.28% reflects a shrinking operating margin that dropped from 0% to 0% over the same period. Shareholders were not prepared for this moderation in revenue, which added to the concern surrounding the company's financial performance.
Protokinetix Incorporated

Protokinetix Incorporated Announces an Operating Profit of $0.115577 Million for Q2 2023, Amid Stiff Competition in the Major Pharmaceutical Preparations Sector

As a journalist covering the financial sector, I have been closely monitoring the earnings reports of various companies in the Major Pharmaceutical Preparations sector. Today, I am focusing on Protokinetix Incorporated (PKTX) and its recent financial results.
In the second quarter of 2023, PKTX reported an operating profit of $0.115577 million. While this may seem like a significant decline compared to the operating profit of $0.442153 million in the same period last year, it is important to consider the context of the current state of affairs for the company. PKTX experienced a shortfall of $-0.116 million in the second quarter of 2023, which is a concerning development considering the company was profitable in the same quarter of 2022.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com